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Abstract
Purpose: Retinopathy of prematurity (ROP) is a leading cause of preventable blindness worldwide. 
Numerous studies have attempted to identify the many risk factors for this condition. While risk factors 
have been identified in previous studies, there remains a lack of information specific to the South 
African population. The purpose of this study was to try and identify possible risk factors in an African 
population that may differ from studies done in other areas of the world. Secondarily by identifying 
important risk factors in South African population, screening could be further tailored to try and 
decrease the load on a very strained health system as well as aiming education for smaller hospitals to 
try and manage babies correctly to decrease the prevalence of this devastating disease.
M ethods: Medical information from an eight-year period for infants with proven ROP that required 
treatment and for their mothers was reviewed from three public sector hospitals in Gauteng. A matched 
control group of babies who did not present with ROP were compared to the ROP group.
Results: There were 64 babies in the treatment group and 63 babies in the control group (no ROP). 
Results showed that babies with ROP were significantly smaller (mean birthweight of 1064g compared 
to 1210g), had a shorter gestational age (average of 28.3 weeks compared to 29.9 weeks) and were 
significantly more likely to receive a blood transfusion.
Weaker evidence showed that the babies with ROP all received oxygen therapy, were more likely to 
undergo mechanical ventilation, receive nitric oxide and have neonatal sepsis. The treatment group also 
showed a trend towards having a higher likelihood of hypotension and hyperglycaemia (requiring 
insulin).
The ethnicity of the babies did not differ between groups with most of the babies being African (96% 
and 94% respectively, ROP and control groups). The prevalence of HIV between and within groups 
could not be reliably established due to lack of available data.
Conclusion: Well documented risk factors as well as some lesser established risk factors were shown 
to predict ROP in this population group. The lack of note keeping of important risk factors by attendant 
medical staff proved problematic and requires attention. The current ROP-screening guidelines in use 
in South Africa (screening babies of under 1500g) are acceptable and should not be reduced if 
economically possible, to the guidelines used in some first world countries (screening of babies under 
1250g) as this would increase the chances of missing the diagnoses of ROP (7 out of 63 treated babies 
in this study’s treatment group would have been missed) in premature infants.
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CHAPTER ONE - INTRODUCTION
The long term  visual outcom e for children w ith retinopathy o f  prem aturity (ROP) include an 
increased risk for blindness and visual disability. Identifying the risk factors and understanding 
the pathogenesis are crucial for the treatm ent and ultim ately the prevention o f  ROP.
P ro b le m  s ta te m e n t
As has clearly been docum ented, South A frica has becom e part o f  the so called “3rd epidem ic 
o f  retinopathy o f  prem aturity” .1,2,3 The increase in prem ature infant survival has been prim arily 
responsible, w ith the associated com plications o f  the condition, including blindness. In South 
A frica, w e are still seeing num erous infants w ith severe RO P requiring treatm ent. O f concern 
is that often the condition is discovered too late w ith irreversible dam age resulting.
Ju s tific a tio n
G uidelines have been established for the m anagem ent o f  ROP, such as those from  the A m erican 
A cadem y o f  Paediatrics and the Royal College o f  O phthalm ologists, how ever these are tailored 
to  first w orld countries w ith w ell-resourced m edical centres. South A frica currently adopts the 
Royal College recom m endation o f  screening infants under 1500g birthw eight. In a study 
undertaken at Chris Hani B aragw aneth H ospital it w as found that no patients over a w eight o f 
1250g at birth developed ROP. Thus, it is suggested that by follow ing the Cryotherapy-R O P 
trial and only screening babies o f  a birth  w eight under 1250g there could be a significant saving 
o f  resources and screening tim e. 4 O f  additional im portance is the South A frican population 
dem ographic: disease profile and risk factors differ considerably from  those first w orld 
countries. 5
A dditional barriers to  overcom e in the South A frican context include the relatively few  trained 
ophthalm ologists com pared to  the num ber o f  prem ature babies in the public health sector. 
A ccording to  the W orld H ealth  O rganization there are m ore than  1.2 m illion babies born 
annually in South A frica and around 14% are born prem aturely. This equates to  around 168 
000 babies possibly needing RO P screening.6 W ithin the public health setting there are 
additional difficulties in transporting ophthalm ologists or the infants to  larger and m ore 
specialized m edical centres for screening and the relative lack o f  resources for the m anagem ent 
o f  R O P country-wide.
As RO P is a preventable disease, identification o f  specific risk factors in the South African 
population dem ographic could facilitate the developm ent o f  a very specific, m ore stream lined 
screening program m e w hich w ould m ean im proved and tim eous treatm ent o f  affected 
prem ature babies.
STUDY AIM
This study aim ed to  assess the risk factors in both prem ature babies and their m others from  
w ithin the South A frican population dem ographic.
O b jectives
To identify the risk factors in already active (five contiguous or eight clock hours o f  extraretinal 
neovascularization) RO P infants requiring treatm ent.These include infant factors such as
birthw eight, gestational age, oxygen therapy, ventilation, chronic lung disease, nitric oxide use, 
infant w eight gain, hypotension, neonatal infections, blood transfusion and hyperglycaem ia. 
M aternal characteristics under investigation include ethnicity, associated pre-eclam psia, 
chorio-am nionitis or other m aternal infections and breastfeeding.
Secondarily  by identifying im portant risk factors in the South A frican population, screening 
could be further tailored to  try and decrease the load on a very strained health  system  as well 
as educating the staff involved in the m anagem ent and care o f  these babies in sm aller hospitals 
to  try and decrease the prevalence o f  this devastating disease.
LITERATURE REVIEW
R etinopathy o f  prem aturity is a vaso-proliferative disorder o f  the developing retina, that occurs 
m ainly in preterm , very low  birth w eight (<1500g) new -borns, often subjected to  hyperoxic 
conditions. 1
Epidemiology
W orldw ide about 10 percent o f  births are preterm  (before 37 full w eeks o f  gestational age). 
Estim ates suggest that RO P is a cause o f  blindness in at least 50 000 children in countries w ith 
levels o f  developm ent ranging from  low  to  h igh .1 R O P w as first described as “retrolental 
fibroplasia” by Terry in 1942.2 This w as the first epidem ic o f  the disease and seen w ith the use 
o f  unm onitored oxygen therapy for the treatm ent o f  respiratory problem s in prem ature infants. 
A t that point in tim e R O P becam e the single m ost com m on cause o f  childhood blindness in 
high incom e countries.3 In 1952 Patz and colleagues dem onstrated in a clinical study the 
association betw een oxygen and R O P.2 This caused the use o f  oxygen to  be dram atically 
restricted w hich led to  a decrease in blindness from  RO P, but also an increased rate o f  m ortality 
and m orbidity over the follow ing few  decades.
W ith the introduction o f  neonatal intensive care units in the early 1970's, a second epidem ic o f 
RO P in high incom e countries developed. This w as later controlled by im provem ents in the 
neonatal IC U  care as well as the introduction o f  retinal ablation therapy (in the form  o f 
cryotherapy).3
The so called “th ird  epidem ic o f  R O P” is now  occurring w ith increasing incidence as m ore 
prem ature infants survive due to  im proved neonatal care.3
South A frica is form ing part o f  this. Each year over a m illion babies are born in South Africa, 
87 percent in public healthcare sector including alm ost h a lf  o f  this in district level facilities. 
D ata suggest that 12.8 percent o f  babies born in the public sector have a birth w eight o f  under 
2500g.5
A pproxim ately 168 000 babies are at risk o f  RO P and require screening each year.1 This 
necessitates the im plantation o f  accurate screening program m es, w ith as m uch inform ation as 
possible about the risk factors to successfully m inim ise the consequences o f  R O P.5
Pathogenesis of ROP
In the hum an, the retina has no blood vessels until the fourth m onth o f  gestation at w hich tim e 
vascular com plexes from  the hyloid vessels at the optic disc grow  tow ard the periphery o f  the 
retina. These vessels reach the nasal periphery after 8 m onths o f  gestation but only reach the 
tem poral periphery about 1 m onth after norm al term  delivery.7 A ngiogenesis is stim ulated by 
“physiologic hypoxia” o f  the developing retina, that is w hen the m etabolic dem ands o f  the 
m aturing neural retina outpace the oxygen supplied by the underlying choroid and the 
encroaching vascular netw ork. V asoactive factors (particularly vascular endothelial growth 
factor [VEG F]) are secreted by the avascular retina, w hich stim ulate new  vessel form ation.2
R etinopathy o f  prem aturity can be v iew ed as the arrest o f  the norm al retinal neuronal and 
vascular developm ent in the preterm  infant, w ith ultim ately pathological com pensatory
m echanism s that result in aberrant vascularisation o f  the retina. The m ore profound the 
im m aturity at birth and the persistence o f  developm ental cessation due to  exposure o f  the retina 
to  harm ful factors, as well as deficiency o f  factors usually  provided in utero the m ore aggressive 
the later pathological response.8
Risk factors associated with ROP
RO P is a m ultifactorial disease w ith m any risk factors and m ediators involved. O ngoing 
research is done to  determ ine the factors involved and to  help us prevent blinding com plications 
o f  this disease and to  im plem ent effective screening program m es.
Infant Risk Factors
G e sta tio n a l age a n d  b ir th  w eigh t
L ow  birth w eight and prem aturity are established risk factors for ROP. Both factors are related 
to  the extent o f  the im m aturity o f  the retina and its vascular developm ent at birth. It has also 
been found the low er the gestational age and birth  w eight the greater the loss o f  factors 
norm ally provided to  the foetus by the intrauterine environm ent.1,2,3 The im m ature fetus is 
unable to  take over this production at such an early stage. A n added insult is that the low  
gestational age increases the duration o f  the in fan ts’ exposure to  postnatal insults w hich also 
contributes to  the infan ts’ risk o f  ROP.
Studies have also shown in utero grow th restriction to  be a risk factor for R O P.8 
D ata from  10,481 babies, o f  w hich 643 developed sight threatening RO P have been analysed 
in preparation for the 2008 U nited K ingdom  guidelines. All the babies fell into the existing 
criteria o f  gestation less than 32 w eeks and/or birth  w eight o f  1500g or less. H ad the G A  criteria 
been reduced by one w eek or birth  w eight by 250g, 9 babies requiring treatm ent w ould have 
been m issed. Thus, the criteria have not been changed m uch, bu t recom m endation w as m ade 
to  screen babies from  betw een 31-32 w eeks’ gestation and 1251g-1501g.9
It is also im portant to keep social dem ographics in m ind, as neonatal care in high incom e 
countries is relatively uniform ly excellent, w hereas m iddle-low  incom e countries m ay range 
from  excellent to  poor neonatal IC U  care and babies o f  greater m aturity have been seen to 
develop RO P. R ecent publications from  India illustrate this issue w ith babies o f  less than 
36w eeks gestational age and greater than 2500g birth  w eight requiring treatm ent.9
O xygen th e ra p y
This is also a w ell-established risk factor o f  R O P since the 1950’s. Since then several studies 
have been done to  try and establish the best possible oxygen saturation to  prevent RO P and yet 
still be effective enough to  prevent infant m ortality and m orbidity .1,2,3
Tin and colleagues reported that in infants w ith a gestational age o f  less than 28 w eeks at birth 
and an oxygen saturation (m easured w ith pulse oxim etry) o f  88-98%  for the first 8 w eeks o f
life, needed treatm ent for R O P four tim es as often than those w ith a saturation target o f  70­
90%. N o difference in survival or cerebral palsy w ere seen.8
O xygen saturation targets o f  85-89%  and 91-95%  have been com pared in tw o large, 
m ulticentre, double b lind random ised studies. The SU PPO RT trial consisted o f  1316 infants 
born from  24-27 w eeks and six days’ gestational age. It show ed that infants in the low er 
saturation group had slightly increased m ortality (20%  vs 16%). B ut a significantly sm aller 
percentage developed retinopathy o f  prem aturity (9%  vs 18% ).8,9
A nother theory that is being studied is the possibility that oxygen in phase 2 o f  RO P could 
suppress high concentrations o f  oxygen regulated grow th factors such as VEG F that cause 
proliferative disease. In a m eta-analysis o f  ten  studies, Chen and colleagues show ed that the 
need for oxygen is different at different stages o f  ROP. L ow  saturation (70-96% ) in the first 
few  postnatal w eeks and higher oxygen saturation (94-99% ) at 32 w eeks’ postm enstrual age or 
older w ere both associated w ith decreased risk for progression o f  R O P.5,8
A lso o f  im portance is that fluctuations in oxygen saturation during the first 8 w eeks o f  life are 
associated w ith higher risk o f  progression to  severe R O P.8
Thus, it is o f  utm ost im portance to  set out appropriate guidelines for neonatal staff to  follow  
regarding the strict m anagem ent o f  oxygen control to m inim ise fluctuations, as well as the 
avoidance o f  high saturation especially in phase one.
M ech an ica l v en tila tio n
D uration o f  artificial ventilation has been found to  be a significant risk factor for ROP. Seiberth 
and L inderkam p show ed artificial ventilation for m ore than seven days to  be a risk factor for 
R O P .10 A  study in 2009 by N ow adzky et al dem onstrated the use o f  the bubble CPA P was 
associated w ith im proved pulm onary outcom es in very low  birthw eight infants com pared to 
conventional m echanical ventilation. U nfortunately, it w as also shown to have double the 
incidence o f  R O P as com pared to  m echanical ventilation. CPAP has been shown to be a 
significant risk factor for R O P .11
C h ro n ic  lu n g  disease
C hronic lung disease has been shown to be independently  related to the presence o f  ROP. It is 
also o f  interest that low  gestational age and chronic lung disease have been shown to have 
synergistic effects and that together they have a higher risk for the progression o f  R O P than 
each risk factor on its ow n.12
In h a le d  n itr ic  oxide
Treatm ent w ith nitric oxide for hypoxic pulm onary failure has been found to  be a risk factor 
for R O P .10 Inhaled nitric oxide vasodilates the pulm onary vasculature through relaxation o f  the 
sm ooth m uscle cells thus prom oting oxygenation. D ue to  its rapid effects, it is also associated 
w ith large fluctuations in arterial oxygen saturation and this is another know n risk factor for
R O P .10 There is how ever some doubt as to  w hether inhaled nitric oxide is correlated to  use o f 
supplem ental oxygen, artificial ventilation and the length o f  stay in the neonatal ICU. How ever, 
in the study o f  the nationw ide inventory o f  risk factors for R O P in the N etherlands, inhaled 
nitric oxide w as still a significant risk factor after the correction o f  the variab les.10
O m ega-3  long  ch a in  p o ly u n sa tu ra te d  fa tty  acids
The im portance o f  om ega-3 long chain polyunsaturated fatty acid and docosahexaenoic acid 
has been show n through m ouse studies. In the third trim ester o f  pregnancy there is a m assive 
transfer o f  essential fatty acids from  m other to  fetus. This does not occur in preterm  birth. 2 The 
principle om ega 3 fatty acid is D H A  and m ain retinal om ega 6 fatty acid is arachidonic acid, 
the balance betw een these tw o fatty acids affects retina vasculature and neuronal survival. A  
deficit o f  om ega 3 fatty acids has been shown to increase risk o f  R O P in anim al m odels.
The effects o f  om ega 3 D H A  supplem entation have been show n to be as strong as anti-VEG F 
therapy in the m ouse m odel.2
P o o r  e a rly  w eigh t ga in  a n d  in fa n t n u tr itio n
It has been reported that there is an association betw een poor early w eight gain and the risk o f 
developing severe ROP. Inadequate nutritional status m ay affect norm al retinal developm ent 
due to  protein/calorie deficiency as well as vitam in deficiency.1
Enteral protein intake and w eight gain are directly associated w ith the concentration o f  IGF-1. 
The W IN R O P (w eight IGF-1 N eonatal R O P) algorithm  w as developed in 2006 and uses the 
rate o f  postnatal gain as a reflection o f  IGF-1, or uses w eight gain and IGF-1 levels together as 
highly predictive m arkers for infants at increased risk o f  developm ent o f  proliferative ROP. It 
can be used to  identify patients w ho will develop proliferative R O P up to  5 w eeks before 
treatm ent is needed.2
Inositol is a carbohydrate found in high concentrations in breastm ilk  and low er serum  levels 
are found in preterm  infants w ho have received prolong parenteral feeding. This has been 
associated w ith ROP. A lso o f  nutritional im portance is V itam in E. V itam in E  tends to  increase 
RO P and blindness but increase risk o f  sepsis. This in turn  causes a “catch 22” situation, as 
sepsis is associated w ith increased risk for R O P .1
In su lin -lik e  g ro w th  fa c to r
IGF-1 has been shown to be critical in both phase 1 and 2 o f  developm ent o f  ROP. In prem ature 
infants, the sudden loss o f  m aternal nutrients and factors contributes to  the dram atic reduction 
in IGF-1. IGF-1 is very im portant in angiogenesis and so a m inim al level o f  IGF-1 is required 
for vascular growth, thus explaining poor vascular grow th in prem ature infants. This is 
supported by the increase grow th and decreased RO P after early IGF-1 treatm ent seen in m ouse 
pups.2
In fla m m a tio n  a n d  In fec tio n  in  in fan ts
L ow  birth w eight prem ature infants are very susceptible to  infection. It has been suggested that 
the exposure o f  the preterm  infant to  infectious and inflam m atory m ediators is associated w ith 
the increased risk o f  developing RO P. This has been proven in m ultiple studies such as ELG A N  
study.3
M ultiple epidem iologic studies have show n that prenatal, perinatal and postnatal system ic 
inflam m ation is an additional risk factor.
H y p erg ly caem ia  a n d  in su lin  use
R aised neonatal glucose concentrations are a proven risk for R O P developm ent. In a study o f 
372 infants born at a gestational age o f  less than 30 weeks, increased nutrition alone caused 
hyperglycaem ia w hich required insulin use. These w ere both associated w ith an increase in 
R O P.8
E ry th ro p o ie tin  (E P O )
EPO  is an oxygen related grow th factor. Its m ain function is on erythrocyte production in the 
bone m arrow  but it also has a role in angiogenesis and retinopathy independent o f  VEGF. It 
has been suggested that early EPO  supplem entation in the first phase can prom ote vascular and 
neuronal survival, how ever i f  given late during phase tw o it can exacerbate proliferation. 13
B lood tra n sfu s io n s
It has been shown that frequent blood transfusions are associated w ith RO P developm ent. 
N ew born babies are transfused w ith adult packed red blood cells w hich have low er affinity for 
oxygen than fetal haem oglobin. This causes increased oxygen delivery to the retina. A lso 
associated is the lifespan o f  the transfused red blood cells w hich is shorter than in adults and 
so causes an overload o f  free iron, w ith increased free radical production and resultant retinal 
damage. 14
H y po tension
It w as shown in a study to exam ine the relationship betw een the cause and severity o f 
hypotension in prem ature infants and the developm ent o f  severe ROP, that dopam ine resistant 
hypotension is a significant risk factor for developing severe RO P. In this study 66%  o f  242 
infants under 28 w eeks’ gestation developed hypotension and o f  these, 25%  w ere dopam ine 
resistant. The only cause related to  the 19% w ho developed severe RO P w as idiopathic 
dopam ine resistant hypotension. L ow  cortisol levels w ere the link betw een the severe R O P and 
the idiopathic dopam ine resistant hypotension.15
Maternal Risk Factors
M a te rn a l  p re -ec lam p sia
Pre-eclam psia has been associated w ith an increased risk o f  ROP. A lthough the exact 
pathogenesis is unclear it seem s that m aternal system ic inflam m ation plays an im portant role 
in developing pre-eclam psia as well as RO P. M any placental factors, cytokines and horm ones 
cause an inflam m atory response and placental ischaem ia leads to  further inflam m ation. 
Inflam m ation has been discussed previously in its role regarding R O P .16
In fla m m a tio n  a n d  In fec tio n  in  m o th e rs
Infants born to m others w ith chorio-am nionitis and leucocytosis have been reported to  be at 
increased risk for R O P .16 Fungal infection has also been linked to  chorio-retinitis and ROP. 
C andida sepsis has been independently associated w ith increased severity o f  RO P needing 
surgical treatm ent.8 This is o f  m assive im portance in our population dem ographic as w e see 
m any cases o f  candida (also due to  H IV ) associations and screening w ith this risk factor in 
m ind could help early prevention and treatm ent o f  at risk infants. This strongly suggests that 
the m aternal factors need to  be taken into account for screening guidelines.
E th n ic ity
It has been shown that being born to  a m other o f  b lack ethnicity is protective tow ards the 
developm ent o f  RO P requiring treatm ent. 1 The reason for this association is unclear. In contrast 
to  these findings a m ulti-ethnic population study in the m idlands region o f  the UK, A sian and 
black infants w ere at greater risk for developing RO P requiring treatm ent com pared to w hite 
infants. This is thought to be related due to  the difference in screening criteria and possibly the 
ethnic ancestry o f  b lack infants in the U K .1
Very little is know n about the incidence as well as the ethnicity risk in South Africa. A  study 
done o f  children in b lind schools in SA show ed 10.6 percent w ere due to  R O P and o f  this only 
1.25 percent w ere o f  b lack population.4 This m ay be due to  the socioeconom ic differences or 
lim ited access to  m edical or other care.
D elport et al. reported a frequency o f  24.5 % o f  RO P in a black  hospital w ith 6.4 % developing 
stage three disease and 4.2 %  requiring treatm ent.17 Retinopathy o f  prem aturity in a South 
A frican tertiary hospital showed a slightly low er percentage o f  RO P-16.3 %  and 1.6 % 
requiring treatm ent.4 South A frica needs m ore inform ation on our population dem ographics 
associated w ith RO P, as well as standardized screening program m es that suit our countries 
ethnicity, socio-econom ic circum stances and governm ent health program m es.
B re a s t m ilk
M other’s m ilk and colostrum  provide m any unique nutrients including D H A  (decosahexaenoic 
acid), horm ones and grow th factors including IGF-1. M ost preterm  babies require parenteral 
nutrition as they require m ore nutrients than w hat enteral feeding can give them . B reast feeding
and RO P risk have had m any contradictory results w ith some studies showing protective results 
and others no association. Further studies are needed to  clarify this association.18
B enefic ia l fac to rs  p rev e n tin g  d ev e lo p m en t o f R O P
Prenatal glucocorticoid steroids as well as fem ale sex have shown to have a low er incidence o f 
ROP. H iggens et al. have described the role o f  antenatal steroids given before birth, causing 
lung m aturation .10 Previous research has also shown that b lack m aternal ethnicity is associated 
w ith decreased severity o f  RO P, how ever some studies have shown increased risk. M ore 
research is clearly needed to  determ ine i f  there is any conclusive evidence. 10
C ontrary to  this finding, B inet et al. found no difference betw een m ale and fem ale sex and 
developm ent o f  RO P. H ow ever, it was shown that m ale infants w ere m ore likely to  die or have 
adverse outcom es. 10
Study Design
The study w as designed as a retrospective investigation o f  all infants w ith established 
retinopathy o f  prem aturity w ith adequate m edical records w ho required treatm ent in St John 
Eye H ospital (SJEH), Charlotte M axeke Johannesburg A cadem ic hospital (CM JA H ) and H elen 
Joseph H ospital (H J).The patients w ere found by evaluating the theatre logbooks (as these 
patients w ould have received treatm ent in theatre for RO P) and getting the patien t’s hospital 
num ber, date o f  birth and nam e and surnam e. This inform ation w as used to  trace files in both 
the ophthalm ology departm ent and the paediatric departm ent.
A nalysed records w ere sourced from  the O phthalm ology and Paediatric departm ents, the 
follow ing inform ation w as extracted: birth w eight, birth  age, gender, possible infant and 
m aternal infection, H IV  status i f  known, use o f  infant oxygen and ventilation, use o f  nitric 
oxide, use o f  insulin for hyperglycaem ia, infant hypotension, infant blood transfusions, 
breastfeeding, m aternal age, m aternal ethnicity, m aternal pre-eclam psia or eclam psia and 
w hether the patient w as booked or unbooked.
O nce the inform ation w as collated it w as tabulated in an Excel spreadsheet. Patients w ere 
assessed on the basis o f  R O P screening/diagnosis and w ere allocated to  either the research 
sam ple or a control sam ple grouping. Control cases included babies w ho underw ent screening 
in the C M JA H  for R O P but w ere found to  have no RO P on ocular exam ination. W hile research 
cases w ere defined as babies w ho had confirm ed R O P and underw ent treatm ent in either 
CM JA H  or St Johns eye hospital for this disease.
D escriptive statistics w ere calculated using SPSS for variables w here all data w as available. 
N orm al distribution w as determ ined from  N orm al Q-Q Plots, ensuring that the assum ption o f 
norm ality w as not violated. T-tests w ere conducted on both sam ples and Chi-Square tests w ere 
used to  com pare risk factors betw een groups.
Participants
In c lu sio n  c r i te r ia
All infants w ith established retinopathy o f  prem aturity w ho had undergone treatm ent. 
Treatm ent included laser ablation, cryotherapy and/or anti-V ascular endothelial grow th factor 
intravitreal injections. Infants w ho w ere referred from  peripheral hospitals bu t underw ent 
treatm ent in the included centres will form  part o f  the study.
A  control group o f  patients undergoing screening but w ho do not fulfil the inclusion criteria 
w ere included into the study. These patients w ere found in the three above m entioned hospitals.
E xc lu sion  c r i te r ia
RO P infants that have not undergone treatm ent or have not been treated in the abovem entioned 
hospitals.
S am pling  a n d  in te rv en tio n
This retrospective study included patients w ho had received treatm ent for retinopathy o f 
prem aturity w ithin the three hospitals m entioned. The records w ere exam ined for both the fetal 
and m aternal risk factors and these w ere analysed for significance in our population. These 
com m on risk factors both m aternal and fetal, can aid us in early diagnosis and treatm ent, m ore 
effective screening or possibly even prevention o f  this disease in our country.
D a ta  c a p tu re , co llection  a n d  analysis
The nam es and hospital num bers o f  the patients w ho had undergone treatm ent for R O P w ere 
searched for and recorded. The patient data w as used to  look up files from  the Paediatric 
N eonatal archives and the O phthalm ology archives in the relevant hospitals. (N ote that H elen 
Joseph H ospital refers babies requiring treatm ent to  C M JA H ), and so no data w as ever looked 
for and no inform ation w as ever retrieved from  this hospital. This inform ation w as recorded 
under the data collected at CM JAH . The files w ere review ed for any clinic, hospital and 
discharge notes for both the neonate and the m other and any relevant inform ation was 
docum ented. The control group w as analysed for the sam e m aternal and infant risk factors as 
the retrospective group.
Ethics
This protocol w as subm itted to  the Ethical S tandards Com m ittee for research involving hum an 
participants at the U niversity o f  the W itw atersrand and received clearance (see A ppendix 1).
Limitations
This w as a retrospective study and depended on the availability o f  patient files and records 
from  the relevant hospitals.
This study also involved not only prim ary academ ic hospitals bu t referrals from  sm aller, 
secondary referral hospitals w ith different standards and level o f  treatm ent as well as possible 
lack o f  equipm ent. This w ould be detrim ental to  proper risk factor analysis bu t w ould also offer 
insight into areas in w hich protocols and treatm ent could be im proved.
This study is lim ited by its confines to  only three treatm ent hospitals in a single city in South 
Africa.
Study sample
The number of infants included in the treatment study group were 39 babies from CMJAH and 25 babies 
from SJEH, with a total of 64 treated babies. The number of infants included in the control group were 
63 babies from CMJAH (Table 1). The control group was only sourced from CMJAH as it has a proper 
screening form that is used by the Ophthalmologists with proper stats being kept for the last few months 
and so obtaining information on these babies was reliable and efficient.
The hospital where the infants in the control group were born are as follows: 35 in CMJAH, 7 in 
Edenvale hospital, 18 in Far east rand hospital and 3 in OR Tambo memorial hospital.
The hospital where the experimental group infants were born are as follows: 1 in Helen Joseph, 1 in 
Natalspruit hospital, 2 in OR Tambo memorial hospital, 1 in Pholosong hospital and 1 in Vosloorus 
hospital. The other 58 babies’ data for this parameter was not found in the data collected.
T ab le  1: Sum m ary o f  results
R IS K  FA C T O R
C O N T R O L
G R O U P
T R E A T M E N T
G R O U P
African 94% 96%
M a te rn a l E thn ic ity Caucasian - 4%
Coloured 6% -
Sex  o f  B a b y
Male 62% 64%
Female 38% 36%
G e sta t io n  (w e e k s) 29.9±2.4 28.3±1.8*
B ir th w e igh t  (g) 1209.62±378.44 1063.58±192.86*
O x y g e n  T h e ra p y  Rece ived 100% 100%
M e c h a n ic a l V e n t ila t io n  R equ ired 20% 73%
N itric  O x id e  T re a tm e n t 0% 0%
N e o n a ta l S e p s is  P re se n t 43% 60%
H y p o te n s io n  P re se n t 0% 10%
B lo o d  T ra n sfu s io n  R e qu ire d 18% 50%
H y p e rg ly ca e m ia  n e e d in g  In su lin 0% 11%
H IV  S ta tu s: E X P O SE D 0% 40%
W here: bold font and * denotes significant (p<0.05) difference. Results for risk factors denoted as "% "  per sample should 
be interpreted with caution due to frequency of missing data.
Of Importance: Due to the missing data of patient information, especially in the primary sample, statistical analysis was not 
possible for reliable p value results.
Infant Risk factors
G e n d e r
The male to female ratio within and between the experimental group and the control group was very 
similar, ensuring that any ROP-related findings were not associated with the sex of the babies. See 
Figure 1.
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Figure 1: Gender of babies included in treatment and control samples
The following factors represent "good” evidence for risk factors for ROP. O f importance in this data is 
that the treatment group babies were significantly smaller at birth (measured in grams) and they were 
bom after a shorter gestation period (more premature).
TREATMENT CONTROL
■  Male ■  Female
B ir th  w eigh t
The treatment group had a significantly lower weight at birth compared to the control group (p<0.05, 
t=2.607, Figure 2).
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F ig u re  2: B irthw eight (gram s)
Within the treatment group there was valid data for n=43, and missing data for n=21. The mean weight 
for this group was 1063.58 g with a range in birth weight from 720 to 1480 g.
The control group had 63 valid data entries. The mean weight for this group was 1209.62g with a range 
from 710 g to 2730 g.
G esta tio n
The treatment group was shown to have a significantly (p<0.05, t=3.586) shorter gestation period 
compared to the control group (Figure 3).
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F ig u re  3: G estation Period (weeks)
The treatment group had 43 babies with valid data and 21 babies with missing data. The mean age of 
gestation at birth was 28.3 weeks with a range from 24weeks to 32 weeks.
The control group had 63 babies with valid information and the mean age of gestation at birth was 29.87 
weeks with a range from 24weeks to 37 weeks.
The following parameters represented risk factors with "weak” evidence in the current sample.
B lood tra n sfu s io n
In the treatment group, half (50%) of the babies required blood transfusions compared to only 18% in 
the control group.
O xygen th e ra p y
Within the treatment group, 22% (n=14) of babies received oxygen therapy compared to 32% (n=20). 
However, this was calculated with the missing data included. (Treatment n=50, Control n=43). If the 
missing data is excluded, all in both samples then received oxygen therapy.
M ech an ica l v en tila tio n
These results should be reviewed with care due to a large percentage of missing data from the files. 
Ventilation was required for 2% of the control group and 12.5% of the treatment group. Mechanical 
ventilation was not required for 6% of the control group and 5% of the treatment group.
If the data is considered with exclusion of the missing information the trend is that 80% of the control 
group did not need mechanical ventilation, where as 73% of the treatment group did require ventilation.
N itric  O xide
79% of the control group did not receive NO, while 16% treatment group did not receive NO. By 
inference, excluding missing data, no participant in either group received NO treatment.
N eo n a ta l Sepsis
There was no significant difference in occurrence of neonatal sepsis between the treatment and control 
groups. Excluding missing data, sepsis was reported in 43% of the control patients and in 60% of the 
treatment patients.
H y po tension
Excluding the missing data, 100% of control did not present with hypotension, while 10% of treatment 
did present with the condition.
H y p erg ly caem ia  re q u ir in g  In su lin
There were no cases in control group requiring insulin, whereas 11% of treatment group did require 
insulin to combat hyperglycaemia.
Records of HIV exposure and status were poor and thus HIV status as a risk factor in this instance 
represents “very weak” evidence for ROP development.
H IV  S ta tu s
All the patients in the control group (n=63) were HIV negative, while 40% of the treatment group were 
exposed to HIV via an HIV positive mother. The treatment group sample size for whom HIV status had 
been recorded was very small (n=5). This data should be reviewed with caution.
Maternal Risk Factors
M a te rn a l  E th n ic ity
Mothers of African origin were the majority in both samples: 94% control and 96% treatment groups. 
Coloured mothers made up the remainder of the control sample (6%) and Caucasian mothers comprised 
the remainder of treatment group (4%).
CHAPTER FOUR - DISCUSSION
This study aimed to evaluate the infant and maternal risk factors associated with ROP in a specifically 
South African sample. The importance of this would be to develop an effective and applicable screening 
tool in order to detect ROP timeously and facilitate prompt treatment.
Worldwide around 10% of births are preterm (before 37 weeks’ gestation) and according to the World 
Health Organization this number is higher in South Africa, at around 14%.6 8 This equates to 
approximately 168 000 babies in South Africa alone.1 It is estimated that 87% of all the babies born in 
South Africa are born within the public health sector.5 This represents an extreme burden on the health 
care system, specifically for the Ophthalmologists, Paediatricians and of course infants and family 
involved. Babies undergoing screening require multiple examinations and possibly visits to different 
facilities, resulting in stressful situations for both the parents and the infant.1
A new and more specific guideline for screening for ROP in SA would include multiple risk factors that 
would be documented. This would be vital information for further research and detecting ROP in our 
specific population. This would differ from the standardised guidelines such as those from the Royal 
College of Ophthalmologists which currently include only weight and gestation.5
The total number of babies treated within this time frame were 38 babies from St Johns eye hospital (of 
which 25 were included in the study) and 40 from CMJAH (of which 39 were included in the study).
A weakness of the study was due to no data being found in records or incomplete information in medical 
records. This study included information from 2008 and many risk factors now identified as important 
were not common knowledge at that stage and so were possibly not deemed important to be included 
in the patients’ medical notes. As seen in a study done in 2006 at Chris Hani Baragwanath, a large 
number of babies with ROP were lost to follow-up and so affected the results of the study. Ten years 
later lack of data, lost files and poor follow-up is still a major problem.4 Maternal information and risk 
factors were also not routinely documented for the infant cases included in this study.
Infant Risk Factors
G e n d e r
The current study showed that both the control and the treatment group had a very similar ratio of male 
versus female babies and this is important as it cannot cause any confounders in the findings. In a study 
done in the USA nearly two million babies were analysed after preterm labour and it was shown that 
50% of male infants were more likely to born prematurely than female babies. However, this study 
concentration on white woman and so this could be different in our population group.19 The ratio of 
male to female babies who had ROP was almost double (20 male babies versus 11 female babies). There 
are no studies in South Africa with data relating to any sex prevalence of ROP. Worldwide only a few 
studies have mentioned the sex ratio in babies with ROP. Most of these studies do not present sex as a 
risk factor. 20 Only a few show otherwise, with an increased male preponderance such as seen in this 
study. In a study done in Lithuania it was shown that male babies developed ROP twice as often as 
female babies (71 versus 37 babies) .21 Female sex was considered a possible protective factor in one 
study done in Australia and New Zealand. 22
B irth w eig h t
The current findings indicate that babies who develop ROP are of significantly lower birthweight than 
babies who are pre-term yet do not develop ROP. In this study babies with ROP had a mean birthweight
of 1063 grams. The maximum weight of an infant treated with ROP in this study was 1480 grams, 
which differs from a study done at Chris Hani Baragwanath by Mayet et al. where the maximum weight 
was 1250 grams.4,5 It was suggested that screening guidelines be changed to only babies under 1250 
grams to reduce stress on resources, however in this study it has been shown that by doing this ROP 
could be missed. In this study 7 of the 63 babies in the treatment group weighed between 1250g and 
1500g and so 11% would have been missed if  babies only under 1250g were screened.
This correlates with the 2008 United Kingdom guidelines in which 10,481 premature babies were 
screened and 643 developed sight threatening ROP. The babies screened were according to the 
guidelines of less than 1500 grams in weight or under 32 weeks’ gestation. Had the birthweight criteria 
been reduced by 250g then nines babies needing treatment would have been missed.9 In a study done in 
Greece of 189 premature infants, 24 developed ROP and the mean birthweight was 939 grams, which 
is lower than found in our study.12 However, in contrast, high income countries with better neonatal care 
and much stricter oxygen use guidelines often screen babies of less than 31 weeks’ gestation and 
birthweight under 1250 grams. This is done with what is called a ‘sickness” criteria. Should any babies 
over this guideline have any other possible additional risk factors such as sepsis or blood transfusions 
then a recommendation is made to screen them. 9 This would not be advisable in a third world country 
such as South Africa as the premature births often occur in smaller hospitals and clinics and the 
monitoring of oxygen use and any other risk factors is often sub-optimal. By decreasing our screening 
criteria, babies with ROP might be missed leading to irreparable damage. Currently, in India which is 
classed as a low to middle income country, babies have been shown to have ROP if they are less than 
2500 gram birthweight or less than 36 weeks’ gestational age.9 However, increasing our guidelines to 
such parameters would put extreme stress on an already overburdened system. A possible 
recommendation would be to put a “sickness criteria” into our guidelines.
G esta tio n
The current findings indicate that neonates with ROP had a significantly shorter gestation period than 
those who did not develop ROP. The average gestation in the babies with ROP was 28 weeks in this 
study compared to 29.8 weeks in the control group. Premature gestational age is the most commonly 
documented risk factor for the development of ROP.1’7’8’9’10’13’14’15’ Similar gestational age findings have 
been reported by Giapros et al. with a mean age of 27.2 weeks in the group with ROP and a mean age 
of 30.3 weeks in the group with no ROP.12
Worldwide, multiple studies have been done with regard to gestational age and the development of 
ROP. Although they all show that prematurity is a risk factor, the ages differ slightly based on whether 
the country is a first or third world country (thought to be due to the level of neonatal facilities and 
care).7 Studies have been done to try and determine whether various risk factors act synergistically to 
increase the risk of ROP. It was shown that low gestational age and chronic lung disease have a higher 
risk of ROP then the sum of each risk factor alone.12
If more of these relationships could be established it would be easier to try and pinpoint patients at 
increased risk for ROP. In contrast to the previous finding low gestational age along with sepsis and 
oxygen usage were all found to be independent risk factors of each other.12 Of importance is that the 
risk of ROP is higher with lower gestational age as was shown in the CRYO-ROP trial. Babies under 
750 grams were reported to have ROP of any stage in 90 % of patients.3 The earlier a baby is born the 
more extreme the loss of essential factors that are usually supplied by the mother and the placenta. The 
infant is not capable of taking over the production of these factors in its premature state and this leads 
to poor weight gain, increased risk for sepsis, ventilation and transfusions. This is a vicious cycle with 
an increased risk for the development of ROP.7 The findings of this study are the first to confirm this 
risk factor in a South African sample.
B lood T ran sfu s io n s
The current findings suggest that neonates at risk for ROP will require blood transfusions. Fifty percent 
(50%) of the babies in the treatment group required transfusions compared to only 18% in the control 
group. While this information certainly indicates a trend in support of this risk factor, further research 
is required to ratify these findings.
The increased risk for the development of ROP and its association with blood transfusion requirement 
has been noted elsewhere in various studies.14 In a study done by Romagnoli et al. it was shown that 
babies with ROP received almost double the number of blood transfusions.14 The pathogenesis of this 
risk factor is not well understood, however, infants are transfused with adult blood cells and these have 
a lower affinity for oxygen than fetal cells and are most probably leading to an increased delivery of 
oxygen to the preterm baby which directly affects the vascularization of the Retina and the development 
of ROP.14 Future recommendations would include transfusion guidelines and possibly using allogenic 
cord red blood cells which may decrease side effects of using adult blood.14
O xygen T h e ra p y
The current findings show that only 22% of the treatment group received oxygen, compared to 32% in 
the control group. This abnormal statistic compared to worldwide data, is due to most of the data in this 
category being absent from notes collected. In the treatment group 50 babies of the 64 had no 
information regarding oxygen administration in the notes collected. If the missing data was removed 
from both groups and new calculations done, then all the babies in both groups received oxygen. 
Oxygen therapy should be precisely documented in all premature babies and this should be an essential 
recommendation that needs to be made country wide.
Although oxygen saturation levels are better controlled than in previous years we are still far from 
obtaining the optimum level for an exact amount of time that prevents infant mortality but still decreases 
the risk of ROP.8 This level of care and monitoring is part of protocols in most first world countries, 
however in developing countries (especially in the smaller clinic and hospitals), babies are still being 
treated with unmonitored 100% oxygen. 8
Multiple large studies have been done worldwide to try and determine the exact oxygen saturation level 
for the age of the babies, weight and duration. These included the SUPPORT, COT, BOOST and 
BOOST-II trials.8 A combination of the results of these studies was reported in a study protocol, 
NeOProM (Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol).23 This was 
a large study in which 4,911 infants were initially entered and they were divided into a group receiving 
low oxygen saturation (2,456 babies) and a group receiving high oxygen saturation (2,455 babies).23 
This study showed that ROP was decreased if  the oxygen saturation level was low (around 85-89%), 
but that mortality was significantly increased in this group.23 From the outcomes of this major study it 
is currently recommended that oxygen saturation levels are maintained between 90-95%.23
This upper limit needs to be monitored very carefully to try and prevent increasing risk of ROP. Babies 
that undergo fluctuations in oxygen saturation are also shown to have an increased risk of developing 
ROP and all efforts should be made to try and maintain a stable level of saturation that is not over 95%.8 
In South Africa more education and strict guidelines need to be applied to all centres that deliver babies 
to try and decrease the prevalence of ROP.
M ech an ica l V en tila tio n
The outcomes regarding mechanical ventilation in this study should be reviewed with caution as most 
of the data in both the treatment and the control group was missing. Once again, this emphasises the 
importance of strict and complete note-keeping that needs to become part of a nationwide programme. 
However, a trend was noted with the treatment group having almost a 10 times higher rate of babies 
receiving mechanical ventilation. Studies have shown that mechanical ventilation is a risk factor for the 
development of ROP 1, with 100% of babies having ROP receiving mechanical ventilation compared 
to 70% of babies without ROP shown by Giapros et al}2 The longer the duration of mechanical 
ventilation received the higher the risk for the development of ROP.11015
N itric  O xide
The current findings were interpreted with minimal information due to a very high percentage of 
missing data. By calculating the statistics with missing data excluded, neither the treatment group nor 
the control group received nitric oxide. Nitric oxide is used to treat pulmonary failure and it was found 
by Van Sorge et al. that the use of nitric oxide was associated with an increased risk of ROP. It was 
also noted that it was independently associated with the risk of ROP after variables such as concurrent 
oxygen use and mechanical ventilation were corrected for.10 Conversely, Donahue et al. showed that 
although the use of nitric oxide reduced mortality and chronic lung disease, it had no effect on the risk 
of developing ROP.10 More information regarding the use of nitric oxide, the exact dose and the duration 
and its effect on ROP is needed.
N eo n a ta l Sepsis
The data in this study shows that there was no significant difference in the occurrence of sepsis in the 
treatment group compared to the control group. There was a 60% occurrence of sepsis in the treatment 
group and 43% in the control group. Studies have shown that infants who developed sepsis early on had 
an increased risk of developing ROP.16 Of importance, fungal infection has also been associated with 
an increased risk of severe ROP.7 According to Lee et al. it was shown that both prenatal and postnatal 
sepsis was an independent risk factor for the development of ROP.16 The exact mechanism is currently 
unknown however the effect of sepsis on increasing free radical molecules and a lower level of 
antioxidants due to immaturity may play a role 1316
H y po tension
The current data shows that if  the missing data is excluded then 10% of the treatment group were 
diagnosed with hypotension and none of the control group had any hypotension. In some studies, 
hypotension has been shown to be a risk factor for the development of ROP, however this has not been 
a consistent finding.15 Of importance, hypotension commonly occurs with neonatal sepsis and this could 
possibly be the cause of increased risk of developing ROP. In a study done by Catenacci et al. 
Hypotension was shown to be a risk factor for the development of ROP.15
H y p erg ly caem ia
Current data shows that 11% of the treatment group needed insulin to treat hyperglycaemia, compared 
to no babies in the control group. Studies have previously shown that high glucose levels in preterm 
infants needing insulin increase the risk for the development of ROP.8
H IV  s ta tu s
The current data shows that 40% of the treatment group were HIV exposed and all the patients in the 
control group were HIV negative. The sample size of patients with data was very small and so these 
results should be reviewed with caution. In our population group this information would have been very 
important due to the high prevalence of HIV. Note keeping for ROP babies should definitely include 
this information in the future and further studies would be beneficial to see if  this has any effect on the 
risk of developing ROP. In a study done at Tygerberg children’s hospital it was shown that ROP was 
not an associated risk factor.24
Maternal factors
E th n ic ity
In this study, the majority of mothers were of African origin (over 90% in the treatment and control 
group). This is probably due to the population profile that is treated in these hospitals (mainly of African 
origin). This makes the comparison of different ethnicities impossible. The possible effect of ethnicity 
and genetics on the development of ROP is of importance and more research needs to be done in the 
South African population.
It was shown that being of black ethnicity is associated with a decreased risk of developing severe ROP 
in study done by Husain et al.1 In contrast a study examining a multi-ethnic population showed that 
black infants were at higher risk for developing ROP.12 Currently in South Africa more data needs to 
be collected comparing Caucasian, Coloured and African babies to determine who is most at risk in our 
population.
The other maternal factors that were to be collected in this study were age, maternal infection and 
maternal preeclampsia. Due to lack of data in the notes collected his information was almost never 
documented or missing and so no analysis of these parameters could be carried out. This is an important 
recommendation to the department of paediatrics and ophthalmology to always be vigilant about writing 
down all the parameters that may influence the baby developing ROP. Although these factors were 
previously deemed irrelevant it is becoming more apparent through research that multiple factors affect 
the development of ROP and of note this includes maternal infection and pre-eclampsia. In a previous 
study, it was shown that chorio-amnionitis adds to the risk of developing ROP in a premature baby.16
The effect of pre-eclampsia on the development of ROP has had mixed results in studies with some 
showing an increased risk and others showing no risk.16 What would be very important in our population 
is determine if  it has a risk in our population profile. South Africa is a third world country with a high 
rate of HIV and this could cause increased rates of maternal immunosuppression, thus leading to 
increased maternal infection and inflammation. It would be vital to know if this causes an increased risk 
of ROP. Improving maternal care and health would have a widespread effect on both Mother, baby and 
health resources.
CHAPTER FIVE - CONCLUSIONS AND RECOMMENDATIONS
The data reflects important positive and negative findings relating to babies with ROP in the public 
health sector in South Africa. It shows that this population group is more likely to develop ROP if they 
are are of lower birth weight, smaller gestational age and have received blood transfusions. It shows a 
trend towards an increased risk for the development of ROP if they have undergone mechanical 
ventilation, had neonatal sepsis, received nitric oxide, had hypotension and hyperglycaemia. Maternal 
ethnicity was mainly African in origin due to the population subtype and lack of comparison against 
other population groups. HIV as a possible risk factor was not able to be calculated due to lack of 
missing data in these files.
Maternal factors are seemingly becoming more prominent in the possible development of ROP in the 
infant. This is thought to be due to risks causing preterm birth as well as possible inflammatory and 
circulating factors from the mother that could affect the infant. More information regarding mother’s 
health and HIV status is vital to determine if  this is true.
A weakness of this study was not the lack of babies that have been treated for ROP in this study, but 
rather a lack of relevant information in the notes collected at the various hospitals. Many new risk 
factors have emerged in the last few years other than just gestational age and oxygen use. These 
important possible risk factors need to be documented in a proper fashion by both the paediatrician and 
the ophthalmologist if  we are to try and prevent this devastating disease. By proper note keeping and 
implementation of proper guidelines not only in larger hospitals but in all clinics that have the facilities 
for childbirth, we could clamp down on babies at risk and implement better screening and faster 
treatment.
Of importance, in this study 7 babies over the weight of 1250g (but under 1500g) were noted to have 
developed ROP (equates to 11% of the treatment group). This is in contrast to previous research done 
in South Africa. In keeping with these findings, our screening criteria should not be reduced to screening 
babies only under the weight of 1250g as being done in some first world countries if at all possible. 
Although our screening system is overburdened and screening less babies would make a positive impact 
on all the medical staff involved as well as the families and infant being screened, we stand a risk of 
missing possible blinding ROP. However, we do not need to go to such extremes such as in countries 
like India who screen babies from 2500grams and under. Based on the results of this study screening 
babies under 1500g and including a “sickness criteria” would suffice.
An important recommendation from this study is to implement a standardised neonatal ROP screening 
form that can be used country wide for the documentation of important risk factors both in the infant 
and the mother. I have included a template in appendix 3 that I have designed from this study. If such a 
form was used, we would be able to perform large scale studies with the data and hopefully be able to 
determine exactly which other risk factors are specific to this population. We would be able to determine 
if HIV is a risk factor and whether maternal risk factors are important.
It would show us important information regarding the level of care in smaller hospitals versus larger 
hospitals and where we need to work on healthcare education relating to ROP.
By ensuring properly educated healthcare workers from the nursing staff in primary level hospitals to 
the specialists in the tertiary hospitals we could firstly prevent, secondly screen efficiently with the 
correct risk factors known and if  need be, treat this disease in the best possible manner in our wonderful 
country of South Africa.
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